Janney Montgomery Scott’s Entasis Therapeutics Holdings Inc. ETTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-52,797
Closed -$99K 2483
2022
Q1
$99K Sell
52,797
-20,800
-28% -$37.9K ﹤0.01% 2180
2021
Q4
$161K Buy
73,597
+5,000
+7% +$13.5K ﹤0.01% 2267
2021
Q3
$229K Sell
68,597
-890
-1% -$2.41K ﹤0.01% 2095
2021
Q2
$186K Sell
69,487
-1,443
-2% -$3.26K ﹤0.01% 2146
2021
Q1
$152K Buy
70,930
+8,267
+13% +$23.5K ﹤0.01% 2097
2020
Q4
$155K Buy
62,663
+10,425
+20% +$20.5K ﹤0.01% 2133
2020
Q3
$107K Sell
52,238
-2,660
-5% -$7.59K ﹤0.01% 1993
2020
Q2
$162K Buy
54,898
+3,343
+6% +$9.14K ﹤0.01% 1871
2020
Q1
$136K Buy
51,555
+3,400
+7% +$15.3K ﹤0.01% 1744
2019
Q4
$239K Buy
48,155
+1,294
+3% +$7K ﹤0.01% 1829
2019
Q3
$279K Buy
46,861
+1,944
+4% +$13K ﹤0.01% 1730
2019
Q2
$290K Buy
44,917
+2,125
+5% +$13.7K ﹤0.01% 1714
2019
Q1
$289K Buy
42,792
+1,323
+3% +$7.93K ﹤0.01% 1692
2018
Q4
$169K Buy
+41,469
New +$273K ﹤0.01% 1804

Other funds holding ETTX

Janney Montgomery Scott's ETTX Position: Q2 2022 in Review

Janney Montgomery Scott sold out of Entasis Therapeutics Holdings Inc. (ETTX) in Q2 2022, closing a stake of 52,797 shares — an estimated $99K sold.

Janney Montgomery Scott first reported a position in ETTX in Q4 2018 and held it in 14 quarters. The position peaked at $290K in Q2 2019. 27 funds tracked by Wall St. Rank hold ETTX as of Q2 2022.

  • Janney Montgomery Scott reported no remaining Entasis Therapeutics Holdings Inc. position as of Q2 2022 after selling out during the quarter.
  • Janney Montgomery Scott sold 52,797 Entasis Therapeutics Holdings Inc. shares in Q2 2022, an estimated $99K.
  • Janney Montgomery Scott first reported a position in Entasis Therapeutics Holdings Inc. in Q4 2018 and held it in 14 quarters.
  • Janney Montgomery Scott's Entasis Therapeutics Holdings Inc. position peaked at $290K in Q2 2019.
  • 27 funds tracked by Wall St. Rank held Entasis Therapeutics Holdings Inc. as of Q2 2022.

Based on Janney Montgomery Scott's 13F filing for Q2 2022, filed 3 Aug 2022.